The Phase III, randomized, multicenter, open-label, CheckMate 649 study compared nivolumab in combination with platinum fluoropyrimidine-based chemotherapy versus chemotherapy alone in treatment-naïve subjects with advanced/metastatic gastric or esophagogastric cancer. HER-2 positive individuals were excluded.
“It was the first study that showed an overall survival greater than one year in patients with HER-2 negative advanced gastric adenocarcinoma”, comments clinical oncologist at the Institute of Hematology and Oncology of Curitiba (IHOC), clinic of Grupo Oncoclínicas, Noelle Suemi. Wassan.
At minimum 12-month follow-up for 1581 randomized patients, the combination of nivolumab + chemotherapy had a statistically significant overall survival benefit versus chemotherapy in all patients. A progression-free survival benefit was also observed, with a 23% lower chance of recurrence in patients who received nivolumab.
Access our website and read the full article with all the details of this study.